This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday
This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday
View filing at SEC.gov →5 most recent filings and news items mentioning AXSM. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/AXSM/news?limit=20"
Pull AXSM filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayThis Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday
View filing at SEC.gov →Axsome Therapeutics announced the FDA accepted its NDA for AXS-12 to treat cataplexy in narcolepsy, setting a PDUFA target date of May 1, 2027. This regulatory milestone advances the biopharmaceutical company's CNS pipeline and creates a path to market.
View filing at SEC.gov →Axsome Therapeutics adopted an Executive Severance and Change in Control Plan effective June 5, 2026, to provide severance benefits to key employees upon involuntary termination. The plan supersedes prior severance arrangements and is intended to retain executive talent during or
View filing at SEC.gov →10 Health Care Stocks Whale Activity In Today's Session
View filing at SEC.gov →Axsome Therapeutics resolved all patent litigation related to SUNOSI (solriamfetol) by settling with the remaining first-to-file generic applicant, allowing five companies to sell generic versions starting September 1, 2040 (or March 1, 2040 if no pediatric exclusivity). The sett
View filing at SEC.gov →